Medindia

X

Patheon signs technology transfer agreement with Dendreon

Thursday, August 5, 2010 News on IT in Healthcare J E 4
Advertisement

RESEARCH TRIANGLE PARK, NC, Aug. 5 /PRNewswire-FirstCall/ - Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, announced today that it has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE(R) (sipuleucel-T) manufacturing process. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010 for the treatment of asymptomatic or minimally symptomatic castrate resistant (hormone refractory) prostate cancer.

"We are very excited that Dendreon has chosen Patheon to help them bring to market this promising new therapy. Our agreement is further evidence that we are being recognized in the industry as the contract development and manufacturer of choice. We have dedicated ourselves to understanding our customer's needs and developing both the capability and capacity to deliver on those needs. We're happy that Dendreon has trusted us to be part of the commercialization of this product," said Wes Wheeler, Patheon's Chief Executive Officer and President.

PROVENGE is the first autologous cellular immunotherapy to be approved by the FDA and is based on a unique technology platform.

ABOUT PATHEON

Patheon is a leading global provider of contract development and manufacturing services to the pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies. Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API. Patheon's integrated development and manufacturing network of 11 facilities and eight development centers, across North America and Europe, ensures that customer products can be launched timely and confidently anywhere in the world.

www.dendreon.com

SOURCE Patheon Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Norwegian Cervical Screening Program Approves Reim...
S
Utah ACEP Disputes Press Ganey Statistic on Length...